Clinical Trials · NCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 938
- Start date
- Mar 2021
- Locations
- 75 sites, 8 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight